» Articles » PMID: 17234900

Rhesus Monkey Trace Amine-associated Receptor 1 Signaling: Enhancement by Monoamine Transporters and Attenuation by the D2 Autoreceptor in Vitro

Overview
Specialty Pharmacology
Date 2007 Jan 20
PMID 17234900
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor that directly responds to endogenous monoamines as well as amphetamine-related psychostimulants, including methamphetamine. In the present study, we demonstrate TAAR1 mRNA and protein expression in rhesus monkey brain regions associated with monoaminergic systems, variable cellular distribution of TAAR1 in rhesus monkey brain, and TAAR1 coexpression with the dopamine transporter (DAT) in a subset of dopamine neurons in both rhesus monkey and mouse substantia nigra. On this basis, we evaluated rhesus monkey TAAR1 activation by different compounds and its functional relation with monoamine transporters and the dopamine D2 receptor (D2) short isoform (D2s) autoreceptor in vitro using a cAMP response element-luciferase assay. TAAR1 activation by monoamines and amphetamine-related compounds was greatly enhanced by coexpression of dopamine, norepinephrine, or serotonin transporters, and the activation enhancement was blocked by monoamine transporter inhibitors. This enhancement did not occur in control experiments in which the dopamine D1 receptor (D1) was substituted for TAAR1. Furthermore, activation of TAAR1 by dopamine was completely inhibited by D2s when coexpressed with TAAR1, and this inhibition was blocked by the D2 antagonist raclopride. Last, dopamine activation of TAAR1 could induce c-FOS-luciferase expression but only in the presence of DAT, whereas dopamine activation of D1 resulted in equivalent c-FOS expression in the presence or absence of DAT. Together, these data reveal a broad agonist spectrum for TAAR1, a functional relation of TAAR1 with monoamine transporters and D2s, and a mechanism by which D2 receptor drugs can influence brain monoaminergic function and have efficacy through affecting TAAR1 signaling.

Citing Articles

Regulation by Trace Amine-Associated Receptor 1 (TAAR1) of Dopaminergic-GABAergic Interaction in the Striatum: Effects of the Enhancer Drug (-)BPAP.

Harsing Jr L, Szenasi G, Feher B, Miklya I Neurochem Res. 2025; 50(2):94.

PMID: 39903411 PMC: 11794408. DOI: 10.1007/s11064-025-04337-7.


Trace amine-associated receptor 1 (TAAR1): an emerging therapeutic target for neurodegenerative, neurodevelopmental, and neurotraumatic disorders.

Dalvi S, Bhatt L Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39738834 DOI: 10.1007/s00210-024-03757-6.


A Pilot Study on a Possible Mechanism behind Olfactory Dysfunction in Parkinson's Disease: The Association of TAAR1 Downregulation with Neuronal Loss and Inflammation along Olfactory Pathway.

Zhang M, Hong H, Shi Y, Huang W, Xia Y, Tan L Brain Sci. 2024; 14(4).

PMID: 38671952 PMC: 11048016. DOI: 10.3390/brainsci14040300.


G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.

Wong T, Li G, Li S, Gao W, Chen G, Gan S Signal Transduct Target Ther. 2023; 8(1):177.

PMID: 37137892 PMC: 10154768. DOI: 10.1038/s41392-023-01427-2.


Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.

Sukhanov I, Dorotenko A, Fesenko Z, Savchenko A, Efimova E, Mor M Biomolecules. 2023; 13(1).

PMID: 36671394 PMC: 9855999. DOI: 10.3390/biom13010009.